{'52WeekChange': -0.19999999,
 'SandP52WeekChange': None,
 'address1': '675 Arapeen Drive',
 'address2': 'Suite 202',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 1.48,
 'askSize': 3100,
 'averageDailyVolume10Day': 2547387,
 'averageVolume': 1789847,
 'averageVolume10days': 2547387,
 'beta': 0.396078,
 'beta3Year': None,
 'bid': 1.44,
 'bidSize': 4000,
 'bookValue': 0.137,
 'category': None,
 'circulatingSupply': None,
 'city': 'Salt Lake City',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 1.52,
 'dayLow': 1.42,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -4.313,
 'enterpriseToRevenue': 375.395,
 'enterpriseValue': 61936444,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '801-994-7388',
 'fiftyDayAverage': 1.1804,
 'fiftyTwoWeekHigh': 3.45,
 'fiftyTwoWeekLow': 0.301,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 46107479,
 'forwardEps': -0.16,
 'forwardPE': -9.25,
 'fromCurrency': None,
 'fullTimeEmployees': 12,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.03677,
 'heldPercentInstitutions': 0.17764999,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/lipocine.com',
 'longBusinessSummary': 'Lipocine Inc., a specialty pharmaceutical company, '
                        'focuses on the development of pharmaceutical products '
                        "in the area of men's and women's health. Its primary "
                        'development programs are based on oral delivery '
                        'solutions for poorly bioavailable drugs. The company '
                        'has a portfolio of product candidates designed to '
                        'produce pharmacokinetic characteristics and '
                        'facilitate lower dosing requirements, bypass '
                        'first-pass metabolism in certain cases, reduce side '
                        'effects, and eliminate gastrointestinal interactions '
                        'that limit bioavailability. Its lead product '
                        'candidate is TLANDO, an oral testosterone replacement '
                        "therapy. The company's pipeline candidates also "
                        'include LPCN 1111, an oral testosterone therapy '
                        'product for once daily dosing that completed Phase II '
                        'testing; LPCN 1107, an oral hydroxyprogesterone '
                        'caproate product for the prevention of recurrent '
                        'preterm birth and has completed an end-of-Phase II '
                        'meeting with the Food and Drug Administration; and '
                        'LPCN 1144, an oral prodrug of bioidentical '
                        'testosterone that is in Phase I Clinical trial for '
                        'the treatment of non-alcoholic steatohepatitis. '
                        'Lipocine Inc. is headquartered in Salt Lake City, '
                        'Utah.',
 'longName': 'Lipocine Inc.',
 'market': 'us_market',
 'marketCap': 70861664,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_8057882',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -15553523,
 'nextFiscalYearEnd': 1640908800,
 'open': 1.51,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '801-994-7383',
 'previousClose': 1.48,
 'priceHint': 4,
 'priceToBook': 10.80292,
 'priceToSalesTrailing12Months': 429.49066,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 1.52,
 'regularMarketDayLow': 1.42,
 'regularMarketOpen': 1.51,
 'regularMarketPreviousClose': 1.48,
 'regularMarketPrice': 1.51,
 'regularMarketVolume': 1637775,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 47879500,
 'sharesPercentSharesOut': 0.021300001,
 'sharesShort': 1019147,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 6657061,
 'shortName': 'Lipocine Inc.',
 'shortPercentOfFloat': 0.022,
 'shortRatio': 0.49,
 'startDate': None,
 'state': 'UT',
 'strikePrice': None,
 'symbol': 'LPCN',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.512,
 'twoHundredDayAverage': 0.7109856,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '137197be-0b23-343c-8f5a-babc45642296',
 'volume': 1637775,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.lipocine.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '84108'}